Neal Shore, MD, FACS, shares his final thoughts on the current landscape of clinical trials for both non-muscle-invasive bladder cancer and muscle-invasive bladder cancer, providing insights into the ...

Neal Shore, MD, FACS, discuss the key efficacy outcomes reported for nadofaragene firadenovec (ADSTILADRIN) in the phase 3 trial for patients with Bacillus Calmette-Guérin (BCG)-unresponsive ...

Neal Shore, MD, is the National Urology Research Director for 21 st Century Oncology in Myrtle Beach, SC. He has been extensively involved in clinical trials of medications for treating prostate ...

Neal Shore, M.D., FACS is the medical director of the Carolina Urologic Research Center and is an internationally recognized expert in Urologic Oncology. Dr. Shore is a practicing Urologist at the ...

Neal Shore, MD BARCELONA—Investigators say they have confirmed the long-term efficacy and tolerability of an annual histrelin acetate implant in men with advanced prostate cancer.

SYDNEY, May 26, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in ...